Zentalis Pharmaceuticals, Inc. Increase (Decrease) in Receivables
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Increase (Decrease) in Receivables of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. increase (decrease) in receivables for the quarter ending 2026-06-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in receivables for the quarter ending 2026-03-31 was $0.00.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in receivables for the quarter ending 2025-09-30 was $0.00.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in receivables for the quarter ending 2025-06-30 was $0.00.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | -$5.00M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.00M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | -$5.00M 10-Q · filed 2026-05-12 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |